Transcenta Holding Limited announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Osemitamab, its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, for the treatment of patients with pancreatic cancer.
